Investment
Features
FeesSafety
Academy
More
Pluang+

Park Avenue Securities boosts Pfizer stock holdings by 20.8% amid positive oncology trial results and analyst upgrades.

Market News
22 Mar 2026
Defense World
View Source
Bullish
pluang ai news

Park Avenue Securities LLC increased its Pfizer Inc. stock holdings by 20.8% in Q4, adding 41,031 shares worth nearly $5.93 million. This move comes as Pfizer reported better-than-expected quarterly earnings and positive clinical trial results in oncology, including a successful Phase 3 study for TALZENNA plus XTANDI. Several analysts have upgraded Pfizer’s stock, with HSBC raising its price target to $32, supporting renewed investor interest. Despite a minor stock dip and a mini-tender offer advised against by Pfizer, institutional confidence remains strong with 68.36% ownership.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App